Abstract
The clinical development of antibody drug conjugates (ADCs) in ovarian cancer began in 2008 with farletuzumab, a humanized monoclonal antibody, and vintafolide, an antigen drug conjugate, both targeting alpha folate...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have